Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum inm28-LP
- Development stage
- Preclinical
- Lead developer
- Inner Mongolia Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum inm28-LP is a specific probiotic strain belonging to the species Lactiplantibacillus plantarum. It is primarily recognized for its metabolic benefits, particularly in the context of obesity and lipid metabolism regulation. The strain functions by modulating the gut microbiome, promoting the growth of beneficial taxa, and increasing the production of short-chain fatty acids (SCFAs) like acetate and butyrate. Research indicates that inm28-LP can activate the AMPK signaling pathway, leading to reduced adiposity and improved insulin sensitivity. It is commonly incorporated into dietary supplements and functional foods aimed at weight management and metabolic health, particularly in the Chinese market.
- Other names
- Lactiplantibacillus plantarum inm28-LP植物乳杆菌inm28-LPinm28inm-28inm 28
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SREBP-1 / SREBF1 (SREBP-1)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Lactobacillus plantarum inm28-LP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum inm28-LP.